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A B S T R A C T
Objectives: Several serological SARS-CoV-2 immunoassays have been developed recently but require external
validation before widespread use. This study aims at assessing the analytical and clinical performance of the
iFlash® anti-SARS-CoV-2 chemiluminescence assay for the detection of both IgM and IgG antibodies. The kinetics
of the antibody response was also evaluated.
Design & Methods: The precision, carry-over, linearity, limit of blank, detection and quantification were assessed.
Sensitivity analysis was performed by using 178 sera collected from 154 RT-PCR confirmed COVID-19 patients.
The specificity analysis was performed from 75 selected non-SARS-CoV-2 sera with a potential cross-reaction to
the SARS-CoV-2 immunoassay.
Results: This iFlash® SARS-CoV-2 assay showed excellent analytical performance. After 2 weeks since symptom
onset, the sensitivities for IgM and IgG were 62.2% (95% CI: 52.3–71.2%) and 92.9%% (95% CI: 85.7–96.7%),
respectively by using the cut-off provided by the manufacturer. After cut-off optimization (i.e.> 2.81 for IgM
and>4.86 for IgG), the sensitivity for IgM and IgG were 81.6 (95% CI: 72.7–88.1%) and 95.9% (95% CI:
89.4–98.7%), respectively. Optimized cut-off for IgG improved the sensitivity to reach 100% (95%CI: 87.6–100)
from 28 days since symptom onset.
Conclusions: This study shows that the iFlash® SARS-CoV-2 assay from YHLO biotechnology, has satisfactory
analytical performance. Nevertheless, the sensitivity of the IgM is limited for a proper clinical use compared to
IgG. The determination of anti-SARS-CoV-2 IgG antibodies from 28 days since symptom onset was associated
with high sensitivity, especially using optimized cut-offs (i.e. 100%).
1. Introduction
On December 30, 2019, the city of Wuhan, China, experienced an
outbreak of unexplained pneumonia. On January 7, 2020, a new be-
tacoronavirus, severe acute respiratory syndrome coronavirus (SARS-
CoV-2) was identified. The number of confirmed cases worldwide ex-
ceeds 23 million and the number of deaths worldwide stands at 800,906
deaths [1,2]. The gold standard method for the diagnosis of SARS-CoV-
2 infection is (real-time) reverse transcription polymerase chain reac-
tion (RT-PCR) in respiratory samples [3]. However, the accuracy of
these molecular methods is variable and depends on several pre-ana-
lytical variables such as specimen collection, transport and storage [4].
In addition, clinical factors including time since infection and viral load
also impact the sensitivity of the test [3]. Moreover, RT-PCR is not
expected to detect past infection [5] and requires a high laboratory
workload, skilled operators, valuable instruments and reagents, and
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crucial safety measures [6]. Detection of SARS-CoV-2 antibodies offers
new perspectives. Serology has several roles including the identification
of convalescent plasma donors, the screening of populations to de-
termine exposure and immunity, and the diagnostic, especially in late-
onset patients with a low viral load [7,8].
A wide range of serological immunoassays has been developed by in
vitro diagnostic companies for the detection of SARS-CoV-2 antibodies,
with different antigens target and formats [3,6]. Independent validation
by clinical laboratories are essential to access the analytical and clinical
performance of these assays [3,5–7,9,10] Consequently, the national
Belgian authorities have planned a major validation campaign to assess
the performance of these new-launched serological tests. The aim of this
study was to evaluate the analytical and clinical performance of the
iFlash® SARS-CoV-2 antibodies (IgM and IgG) chemiluminescence assay
(CLIA).
2. Material and methods
2.1. Study design
This retrospective study has been conducted from May 15 to 30,
2020 at the clinical biology laboratory of the Saint Nikolaus Hospital
(Eupen, Belgium). A total of 178 serum samples coming from two
hospitals (the Saint Nikolaus Hospital (Eupen, Belgium; n = 66), and
Clinique St-Luc Bouge, Namur, Belgium; n = 112) were obtained from
154 patients confirmed positive to SARS-CoV-2 by RT-PCR and with
COVID-19 symptoms. Antibody kinetics since the onset of symptoms
was evaluated in the full cohort of patients for which the information
on the onset of symptoms was available.
2.2. Sample collection
Blood samples collected from patients into serum tubes (BD
Vacutainer® 3.5 or 8.5 mL tubes, Becton Dickinson, New Jersey, USA),
K2 EDTA tubes (BD Vacutainer® 4 mL tubes), or lithium-heparin plasma
tubes (BD Vacutainer® 4.0 mL tubes) according to standardized oper-
ating procedure and manufacturer’s recommendations. Blood sampling
was performed according to the recent guidelines [11]. Two hundred
thirty-five sera of patients taken during previous clinical requests for
diagnostic purposes were collected from March 21 to May 30, 2020 and
stored in the laboratory serum biobank at −20 °C. Frozen samples were
thawed one hour at room temperature on the day of the analysis. Re-
thawed samples were vortexed before the analysis.
2.3. Analytical procedure
The iFlash® anti-SARS-CoV-2 (YHLO biotechnology co., LTD,
Shenzhen, China) is a chemiluminescent assay (CLIA) for the in vitro
quantitative detection of IgM and IgG against the SARS-CoV-2 spike
protein (S) and the nucleocapsid protein (N) in human serum and
plasma. The analyzer converts a relative light unit (i.e. RLU) into an
antibody titer (i.e. AU/mL) through a two-points calibration curve.
According to the manufacturer, a titer ≥10 AU/mL is considered po-
sitive (or reactive) for both IgM and IgG [12]. The RT-PCR for SARS-
CoV-2 determination in respiratory samples (nasopharyngeal swab
samples) was performed on the cobas® SARS-CoV-2 E-gene assay and
ORF1ab-gene assay (Roche Diagnostics®).
2.4. Assessment of analytical performance
2.4.1. Precision
Precision was evaluated by using two QC levels and three pools of
human serum. Precision estimations were obtained by means of tripli-
cates measurements of aliquots for a total of 5 consecutive days.
Repeatability (expressed as intra-run CV, %) and reproducibility (ex-
pressed as inter-run CV, %) of the method was calculated. Aliquots were
stored at −20 °C between analysis. Calculation was performed ac-
cording to the Clinical and Laboratory Standards Institute (CLSI) EP15-
A3 protocol [13].
2.4.2. Limit of detection and quantification
The diluent provided by the manufacturer was used as blank sample
to determine the limit of blank (LOB), detection (LOD) and quantifi-
cation (LOQ).
The LOB has been determined by running the blank sample on three
separate occasion to verify that the results are well< 10 AU/mL. The
LOD and LOQ have been determined by running 30 analyses of the
blank sample using the following equations according the SH GTA 04
document – revision 1 of the COFRAC [14].
- LOD = mean of the 30 measurements + 3*standard deviation
- LOQ = mean of the 30 measurements + 10*standard deviation
2.4.3. Linearity assessment
Linearity was evaluated according to CLSI EP-06. A sample with a
high total antibody levels (i.e. for IgM: 334.64 AU/mL; for IgG:
71.57 AU/mL) was analyzed and diluted by a factor 2 on 5 consecutive
dilutions. The manufacturer’s diluent was used for the dilution.
Observed values were compared to the expected ones and polynomial
regression was calculated.
2.4.4. Evaluation of the carry-over
A sample with high total antibody levels (i.e. for IgM: 124.02; for
IgG: 125.67) was analyzed in triplicate (A1, A2, A3) and followed by a
negative sample (i.e. for IgM: 0.49; for IgG: 0.35) also analyzed in tri-
plicate (B1, B2, B3). The carry-over is calculated using this following
equation: (B1–B3)/(A3–B3) × 100. A carry-over below 1% is con-
sidered satisfactory.
2.5. Evaluation of the clinical performance of the iFlash® SARS-CoV-2 IgM
and IgG
2.5.1. Assessment of the clinical specificity
Non-SARS-CoV-2 sera (n = 75) were analyzed for determining the
cross-reactivity. Thirty-eight sera from COVID-19 negative healthy
subjects and 37 sera from patients with a potential cross-reaction to the
SARS-CoV-2 immunoassay were included in this study. Potential cross-
reactive samples included positive HBsAg (n = 3), IgM CMV (n = 8),
IgM parvovirus B19 (n = 1), anti-Treponema pallidum antibody (n = 1),
IgM Borrelia + IgA Helicobacter pylori (n = 1), urinary infection with
Escherichia coli (n = 1), urinary infection with Klebsiella oxytoca
(n = 1), IgM Mycoplasma pneumoniae (n = 1), IgA Chlamydia pneu-
moniae (n = 1), IgG Chlamydia trachomatis (n = 1) and IgM Toxoplasma
gondii (n = 6), direct coombs (n = 1), rheumatoid factor (n = 1),
RAI + (search for irregular agglutinins) (n = 4), anti-TPO antibodies
(n = 1), high level of total IgG (17.40 g/L) (normal range:
7.00–16.00 g/L) (n = 1), high level of total IgM (5.26 g/L)and high
level of total IgG (28.67 g/L) (n = 1). All of these samples were col-
lected before the COVID-19 pandemic and were stored at −20 °C.
2.5.2. Assessment of the clinical sensibility
One hundred and seventy-eight sera obtained from 154 COVID-19
patients were used to calculate the clinical sensitivity. The immune
status of each false negative patients was checked and none was im-
munocompromised.
Samples were subdivided according to different categories since
symptom onset as follow: 0–6 days: 45 sera; 7–13 days: 35 sera;
14–20 days: 37 sera; 21–27 days: 29 sera; 28 days or more: 32 sera.
Clinical sensitivity for SARS-Cov-2 serological test depending on the
onset of COVID-19 symptoms was carried out with the manufacturer's
cut-off (> 10 AU/mL for both IgM and IgG) and with ROC curve
adapted cut-offs (2.81 AU/mL for IgM; 4.86 AU/mL for IgG).
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2.5.3. Evaluation of antibody kinetics since symptom onset
Antibody kinetics since symptom onset was evaluated using the
following time frames (d, days): 0–2 d, 3–5 d, 6–8 d, 9–11 d, 12–14 d,
15–17 d, 18–20 d, 21–23 d, 24–30 d, 31–40 d, 41–62 d. The mean titer
results (and standard deviations) were plotted against the different time
frames. Smoothing splines with four knots were used to estimate the
time kinetics curve.
2.6. Statistical analysis
Descriptive statistics were used to analyze the data. Sensitivity was
defined as the proportion of correctly identified COVID-19 positive
patients since symptom onset. Specificity was defined as the proportion
of naïve patients or healthy volunteers classified as negative. The ROC
area under the curve (AUC) was calculated as the fraction of true po-
sitive and false positive determined according to the manufacturer's
cut-off values for positive results. Samples included for ROC curves
analyses were sera obtained from at least two weeks after symptoms
onset (n = 98), sera selected to assess cross-reactivity (n = 37) and sera
from healthy volunteers (n = 38). Data analysis was performed using
XLSTAT® software (version 2019.2.2, Addinsoft, Paris, France). P
value<0.05 was used as a significance level. Our study fulfilled the




Repeatability and reproducibility results are summarized in Table 1.
Repeatability and reproducibility were ≤7.5% and ≤13.3%, respec-
tively.
3.1.2. Limits of detection and quantification
The limit of blank, detection and quantification were 0.15 AU/mL
and 0.035 AU/mL; 0.242 AU/mL and 0.441 for IgM; 0.052 AU/mL and
0.097 AU/mL for IgG, respectively.
3.1.3. Linearity
Linearity data for anti-SARS-CoV-2 IgM and IgG are summarized in
Supplementary Fig. 1. The regression equation was for IgM was:
Y = 6.0 + 0.98x with a correlation coefficient (R2) of 0.995. The re-
gression equation was for IgG was: Y = −0.45 + 0.46x + 0.008x2
with a correlation coefficient (R2) of 0.988.
3.1.4. Carry-over
The following values have been obtained for the different samples
and the different runs for IgM and IgG: A1 = 124.0 AU/mL,
A2 = 112.15 AU/mL, A3 = 117.96 AU/mL, B1 = 0.49 AU/mL,
B2 = 0.49 AU/mL and B3 = 0.51 AU/mL and A1 = 125.67 AU/mL,
A2 = 123.46 AU/mL, A3 = 125.93 AU/mL, B1 = 0.35 AU/mL,
B2 = 0.32 AU/mL and B3 = 0.34 AU/mL respectively. The calculated
carry-over was −0.0017% and 0.0079%, respectively.
3.2. Evaluation of the clinical performance
3.2.1. Assessment of specificity
The calculated specificity was 98.7% (95% CI: 92.0–100%) for IgM
and 100% (95% CI: 94.0–100%) for IgG by using the manufacturer’s
cut-off (i.e. ≥10 AU/mL). Using optimized cut-off, specificity was
94.7% (95% CI: 86.6–98.2%) for IgM and 100% for IgG (95% CI:
94.0–100%) (Table 2 and Supplementary Figs. 2 & 3).
3.2.2. Assessment of sensibility
Sensitivities for IgM and IgG according to different time categories
since symptom onset are represented in Table 2. Before 14 days since
symptom onset, sensitivities were not sufficient to be reliable in clinical
practice. After 2 weeks since symptom onset, the sensitivity for IgM was
62.2% (95% CI: 52.3–71.2%) and was 92.9%% (95% CI: 85.7–96.7%)
for IgG by using the cut-off provided by the manufacturer. Using the
optimized cut-off, the sensibility for IgM and for IgG (i.e.> 2.81 for
IgM and>4.86 for IgG) were 81.6 (95% CI: 72.7–88.1%) and 95.9%
(95% CI: 89.4–98.7%), respectively. From 28 days since symptoms
onset, the sensitivity for IgG increased to 100% by using the optimized
cut-off (Table 2 and Supplementary Figs. 2 & 3).
3.2.3. Antibody kinetics
The Fig. 1 shows the IgG kinetics at different days from symptom
onset. The IgG kinetics gradually increased from day 0 to day 62, to
achieve highest IgG concentrations between days 31 and 40. The IgM
kinetics increased from day 0 to day 17 and then gradually decrease
from day 18 to day 62. Standard deviations of the mean for IgM were
very large arguing for a higher inter-individual variation compared to
IgG.
4. Discussion
Serological testing is a useful strategy for the diagnosis, the char-
acterization of the course of the disease, for identifying convalescent
plasma donors as well as for epidemiological study, lockdown exit
programs and COVID-19 vaccine development [5,6,8,16]. Being rapidly
developed and flooding the market, these tests need to be evaluated
both in terms of analytical and clinical performance [6,7,9,15]. The
aims of the present study were to evaluate the analytical and clinical
performance of the iFlash® anti-SARS-CoV-2 CLIA assay for IgM and IgG
antibodies with a large cohort of COVID-19 patients, to provide an
external validation of this test and to evaluate the antibody kinetics
since symptom onset.
Repeatability and reproducibility studies had CVs below 7.5% and
11.9% for IgM, and below 5.8% and 13.3% for IgG. Near the optimized
cut-offs, CVs for repeatability and reproducibility were 1.1% and 5.7%
for IgM, and 1.8% and 2.9% for IgG. These results are consistent with
those published recently [16]. The carry-over was negligible for IgM
and IgG antibodies (< 0.01%). We found a LOQ of 0.441 AU/mL for
IgM and 0.097 AU/mL for IgG, which is below the value we found for
the optimized cut-offs (i.e. IgM: 2.81 AU/mL and IgG: 4.86 AU/mL).
The linearity of the dilutions has been performed in order to assess the
ability of the method to provide direct results proportional to the
concentration of IgM and IgG in the test product samples. The results
obtained showed excellent linearity from±330 AU/mL to±5 AU/mL
for IgM and from±70 AU/mL to±2 AU/mL for IgG. Linearity appears
poor at the highest values for IgG as already described on another
platform (data not shown) [17].
A total of 253 sera were included to evaluate the clinical perfor-
mance of the assay in our study. Compared to other studies having
evaluated the iFlash® SARS-CoV-2 assay [16,18], our study included the
Table 1
Mean (AU/mL), repeatability (CV %) and reproducibility (CV %) assessed on
three patient pool and two QC levels.
Mean (AU/mL) Repetability, CV (%) Reproductibility, CV (%)
IgM Pool 1 0.80 4.5 11.6
Pool 2 2.87 1.1 5.7
Pool 3 69.91 1.7 4.6
QC 1 0.21 7.5 11.9
QC 2 22.90 2.9 4.6
IgG Pool 1 0.63 1.9 5.6
Pool 2 5.46 1.8 2.9
Pool 3 71.51 1.1 6.7
QC 1 0.07 5.8 13.3
QC 2 16.20 2.1 3.4
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highest number of COVID-19 patients (n = 154). Infantino et al. and
Plebani et al. included 61 and 64 COVID-19 patients, respectively
[16,18]. Considering the specificity of the assay, we only reported one
false positive IgM result (i.e. serum with high level of total IgM (5.26 g/
L) and high level of total IgG (28.67 g/L). No false positive IgG result
was encountered even in this sample with a high titer of IgG, suggesting
that the specificity of the YLHO platform is higher for IgG than IgM.
False positive IgM results (> 10.0 AU/mL) with two samples from CMV
infected patients and two samples from patients with rheumatic dis-
eases have been described by Infantino et al. [18]. In pre-COVID-19
donors and auto-immune patients, Plebani et al. found 4 false positive
IgM results (> 10.0 AU/mL), but not for IgG [16]. These were in line
with our observations. The sensitivity of the iFlash® SARS-CoV-2 assay
was also evaluated in samples collected at various times since symptom
onset. In our investigation the sensitivity of the test for IgG increased
progressively to reach a sensitivity of 100% (95%CI: 87.6–100%) after
28 days by using an optimized cut-off (i.e.> 4.86 AU/mL). Using the
optimized cut-off (i.e.> 2.81 AU/mL), the IgM sensitivity reached its
higher level (86.5%) between 14 and 20 days since symptom onset.
Nevertheless, it remained globally of less clinical interest compared to
IgG. The high sensitivity observed with the iFlash® SARS-CoV-2 assay
may be explained by its capacity to recognize both the antibodies di-
rected against the spike proteins and the nucleocapside.
Using ROC curve adapted cut-offs (10.0 AU/mL for IgM and 7.1 AU/
mL for IgG), Infantino et al. found sensitivities and specificities of 73.3%
and 92.2%, and of 83.3% and 100%, for IgM and IgG, respectively [18].
However, authors only included 61 COVID-19 patients, did not sub-
divide patients according to days from symptom onset, and selected
patients with a short timeframe inclusion, i.e. from 8 to 17 days only. In
our study, we found that the sensitivity increased with time from
symptom onset to reach its higher level from 28 days. The suboptimal
sensitivities they observed is highly due to a selection bias. Plebani et al.
only included samples collected after 11 days from the onset of symp-
toms, with a mean time interval from symptom of 24 days (standard
deviation± 11 days; range 12–54 days) [16]. They did not categorized
patients according to days from symptom onset, and only included a
limited number of COVID-19 patients, i.e. 64 SARS-CoV-2 patients. In
this study, the use of a redefined cut-off slightly increases the sensitivity
of the assay, from 92.9% to 95.9%.
Existing data support that seroconversion occurs approximately 7 to
14 days after the onset of symptoms [8,19–22]. In our study, the ki-
netics of IgM and IgG was evaluated during a long-term period
(2 months) at regular time intervals (every 3 days) and on a significant
cohort. Anti-SARS-CoV-2 IgG antibodies gradually increased since the
onset of COVID-19 symptoms to achieve a 100% sensitivity from days
28 (Table 2). After 28 days, we observed a plateau phase and we can
assume aslight decrease in IgG levels. This finding is in accordance with
recently published data [23]. Further designed long term studies are
needed to evaluate IgG kinetics and especially the persistence of po-
tentially neutralizing antibodies. Recently there has been some concern
about antibody kinetics and the persistence of these antibodies espe-
cially in asymptomatic patients. They could only be present for 2 to
3 months [24]. In this present study we only had patients with symp-
toms for 2 months maximum.
Before days 14, the improved sensitivity observed when using the
optimized cut-off for IgM compared to IgG was only modest (Table 2).
Padoan et al. have also studied the kinetics of IgM and IgG on a smaller
cohort (i.e. on 37 COVID-19 patients) and observed a 100% sensitivity
for IgG 12 days after the onset of symptoms while a lower sensitivity
(88%) was reported for IgM [25], and further confirmed in another
study [26]. Our investigation confirms the suboptimal sensitivities re-
ported for IgM on a larger study population and using another analyzer
strengthening the hypothesis that IgM measurement may be less re-
levant for assessing the seroprevalence in previously exposed patients.
In conclusion, this study shows that the iFlash® SARS-CoV-2 assay
from YHLO biotechnology, has satisfactory analytical performance. The
determination of anti-SARS-CoV-2 IgG antibodies from 28 days since
symptom onset was associated to high sensitivity, especially using an
optimized cut-off, which strengthens the strategy of cut-off optimiza-
tion for these SARS-CoV-2 serological assays.
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Table 2
Clinical performance of iFlash® CLIA analyzer for anti-SARS CoV-2 IgM and IgG since symptom onset with the manufacturer’s cut-off and with optimized cut-offs.
0–6d 7–13d 14–20d 21–27d ≥28d
IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG
n 45 45 35 35 37 37 29 29 32 32
Cut-off >10 (IgM and IgG) True positive 9 11 16 24 30 33 14 27 17 31
False negative 36 34 19 11 7 4 15 2 15 1
Sensitivity (%) 20.0 24.4 45.7 68.6 81.1 89.2 48.3 93.1 43.8 97.1
95% CI 10.8–34.1 14.2–38.9 30.5–61.8 51.9–81.5 65.4–90.7 74.5–96.2 31.4–65.5 76.7–99.0 28.2–60.7 83.5–99.9
Cut-off >2.81 (IgM) and >4.86
(IgG)
True positive 14 13 27 25 32 34 22 27 26 32
False negative 31 32 8 10 5 3 7 2 6 0
Sensitivity (%) 31.1 28.9 77.1 71.4 86.5 91.9 75.9 93.1 81.3 100





























Fig. 1. Anti-SARS-CoV-2 IgG antibodies kinetics at different days from the onset
of COVID-19 symptoms (179 patients). Mean (AU/mL) and SD are plotted.
Smoothing splines with four knots were used to estimate the time kinetics
curve.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clinbiochem.2020.08.009.
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